Cystic Fibrosis Foundation - Click here for homepage
Stay Informed  |  Volunteer  |  Clinical Trials

In This Section

Quick Links

Find a Chapter

Get Assistance

Get Assistance - Cox Boys
We are here to help people with CF get the insurance coverage they need. Hear how the Foundation helped the Cox family.

Join us on Facebook!  Facebook 
Follow us on Twitter!  Twitter 
  Google+ 
Subscribe to our channel on YouTube!  YouTube  


Bookmark and Share   Print  

New Cayston® Patients May Face Delays in Starting Treatment
 
February 15, 2012

Gilead Sciences Inc. announced today it is facing challenges meeting demand for its inhaled antibiotic Cayston®. The company said it is working as quickly as possible to address this problem, but that at this time it does not know how long the shortage of Cayston will last.
 
During the period of limited supply, Gilead said its highest priority will be to supply Cayston to those who are regularly using the drug. Active Cayston users will be able to refill prescriptions at their specialty pharmacy when they are due to start their next course of treatment.

According to the company, those with new prescriptions for Cayston are likely to encounter delays starting treatment until the shortage is over. People who have a significant medical need for Cayston and no other adequate treatment alternative may be considered for an exception through a separate medical process.

Gilead recommends that doctors consider alternatives for treating their patients until the supply issue is resolved. The problem currently affects the United States only.

The CF Foundation will keep the CF community notified as updates become available.

People with CF and their families who have questions about Cayston should speak with their CF doctor.

For information about the availability of Cayston, visit www.Cayston.com/supply or call the Cayston Access Program at 1-877-722-9786 (1-877-7CAYSTON), between 8 a.m. – 8 p.m. (Eastern time).

The Cystic Fibrosis Foundation is an accredited charity of the Better Business Bureau.